Core Viewpoint - The article highlights a conflict in the biopharmaceutical industry regarding the competition between hyaluronic acid and recombinant collagen, with Huaxi Biological criticizing the notion that hyaluronic acid is outdated, which they attribute to capital-driven speculation [1][4]. Company Performance - Huaxi Biological's performance has declined significantly, with projected revenue for 2024 expected to decrease by 11.61% and net profit to drop by 70.59%, resulting in a market capitalization loss of over 100 billion [1][6]. - In contrast, Juzhi Biological has experienced substantial growth, with a projected revenue increase of 57.2% and net profit growth of 42.4% for 2024, leading to a doubling of its market capitalization [1][6]. Market Dynamics - The article discusses the contrasting market performances of Huaxi Biological and Juzhi Biological, indicating a clear divide in the industry, with Huaxi's stock price falling over 80% from its peak of 309.43 yuan per share in July 2021 to 53.08 yuan per share as of May 20, 2025, resulting in a market cap of less than 25.6 billion [9][6]. - Juzhi Biological's stock has seen a significant increase, reaching a peak of 86.45 HKD, representing a cumulative rise of over 44% from approximately 60 HKD at the end of 2024 [8][6].

Core Viewpoint - The article highlights the conflict between Huaxi Biological and several brokerage firms that support Juzi Biological, criticizing the notion that sodium hyaluronate is outdated and emphasizing the ongoing relevance of hyaluronic acid in the beauty and medical aesthetics industry [1][3]. Company Performance - Huaxi Biological's market capitalization has significantly decreased from over 140 billion yuan in 2021 to approximately 25 billion yuan currently, while Juzi Biological's stock has surged nearly 70% in 2024, elevating its founders to the status of the richest individuals in Shaanxi [2]. - In 2024, Huaxi Biological reported its worst performance since going public, with annual revenue of 5.371 billion yuan, a decline of 11.6% year-on-year, and a net profit of 164 million yuan, down 72.27% [2]. - Juzi Biological, in contrast, has shown robust growth since 2019, with 2024 revenue reaching 5.539 billion yuan, a year-on-year increase of 57.17%, and a net profit of 2.062 billion yuan, up 42.06% [2]. Market Trends - The market is increasingly favoring the field of recombinant collagen due to its excellent biocompatibility and biodegradability, with projections indicating that the collagen-based skincare market may surpass that of hyaluronic acid by 2026, with a compound annual growth rate of 52.6% [3]. - Despite the rise of recombinant collagen, hyaluronic acid remains irreplaceable in the medical aesthetics sector, particularly in filling procedures, and Huaxi Biological continues to hold a competitive edge in this area [3]. Industry Dynamics - Several brokerage firms, including Huafu Securities and Debon Securities, have retracted their reports that were criticized by Huaxi Biological, indicating the contentious nature of the market's perception of recombinant collagen [4]. - The development of recombinant collagen is still in its early stages, with high raw material costs and insufficient research on its applications, suggesting that both hyaluronic acid and recombinant collagen may coexist in the market to meet diverse consumer needs [4].

Core Viewpoint - Huaxi Biological Technology Co., Ltd. (688363.SH) criticized certain brokerage reports for misleading the market regarding the comparison between hyaluronic acid and recombinant collagen, claiming these reports lack scientific basis and are intended to promote a competing product [1][3][6] Group 1: Company Response - Huaxi Biological reported that it has communicated with regulatory authorities regarding the misleading content in brokerage reports and received apologies from some institutions [1][4] - The company emphasized that the reports are part of a broader issue of "hasty capital" creating a false narrative in the market [3][4] - Huaxi Biological expressed disappointment that relevant parties are not engaging in scientific discussions but are instead focusing on social media commentary [4][5] Group 2: Brokerage Reports - The reports in question were authored by multiple brokerage firms, including Huatai Securities and others, which Huaxi Biological claims are biased towards a competitor, Juzhi Biological [3][6] - Analysts involved in the reports defended their work, stating that the content was compliant and based on objective public data, and denied any intent to promote Juzhi Biological [2][7][8] - The reports highlighted the advantages of recombinant collagen over hyaluronic acid in various applications, which Huaxi Biological disputes as lacking scientific evidence [3][6][8] Group 3: Market Context - In 2024, Juzhi Biological reported a revenue of 55.39 billion yuan, a 57.07% increase, surpassing Huaxi Biological's revenue of 53.71 billion yuan, which declined by 11.61% [6] - Juzhi Biological's core brand, Kefu Mei, contributed 82% of its revenue, showcasing the competitive landscape in the beauty and medical aesthetics industry [6]

Core Viewpoint - The article discusses the ongoing debate in the capital market regarding the valuation and relevance of hyaluronic acid, with Huaxi Biological refuting claims that it is outdated, labeling such views as a product of "restless capital" [1][3][9]. Group 1: Company Positioning - Huaxi Biological published an article on May 17, 2023, directly criticizing nine brokerage reports that suggested hyaluronic acid is outdated, asserting that this narrative is misleading and harmful to the industry [1][3]. - The company emphasized the importance of voicing its stance to protect the integrity of the hyaluronic acid industry, which has been developed over decades of scientific research [6][9]. - Huaxi Biological's market share in the global hyaluronic acid market was reported at 44% in 2021, with China accounting for 82% of global sales [6]. Group 2: Market Dynamics - The article highlights a shift in capital market interest from hyaluronic acid to recombinant collagen, with companies like Juzhibio gaining significant market traction [10][15]. - Juzhibio's stock price has surged nearly 70% in 2023, positioning it as a leading player in the beauty and skincare sector, while Huaxi Biological and other hyaluronic acid companies have seen declining performance [10][13]. - The market for recombinant collagen is projected to grow at a compound annual growth rate (CAGR) of 44.93%, reaching 585.7 billion yuan by 2025 [16]. Group 3: Industry Trends - The article notes that the beauty and skincare industry is experiencing rapid shifts, with companies needing to adapt to changing consumer preferences and capital market trends [2][15]. - Huaxi Biological has begun to diversify its product offerings, launching multiple collagen products and obtaining medical device registrations to stay competitive [17]. - The competitive landscape for recombinant collagen is intensifying, with various companies entering the market, indicating that maintaining a leading position will be challenging for Juzhibio [16][17].

Core Viewpoint - The news highlights the rise of Fan Daidi, the new vice president of Northwest University, as a prominent figure in the business world, particularly in the biotechnology sector, due to her significant stake in the listed company, Juzhi Biotechnology, which has achieved substantial market value and success in the industry [1][4]. Company Overview - Juzhi Biotechnology, co-founded by Fan Daidi and her husband Yan Jianya in 2001, has successfully commercialized human-like collagen through genetic engineering, becoming a model for industry-academia collaboration [3]. - As of 2017, Juzhi Biotechnology had established 11 production lines, with its products being used in over 1,000 hospitals across seven countries and regions, achieving cumulative terminal sales of nearly 10 billion yuan [3]. Market Performance - Juzhi Biotechnology went public on the Hong Kong Stock Exchange in November 2022, with Fan Daidi listed as a co-founder and chief scientific officer [3]. - As of May 12, 2023, Juzhi Biotechnology's market capitalization was approximately 836 billion HKD (about 773 billion yuan), contributing significantly to the combined market value of nearly 900 billion yuan for both Juzhi Biotechnology and another listed company, Xi'an Triangle Defense [4]. Leadership and Governance - Fan Daidi was appointed as the vice president of Northwest University on April 1, 2025, after serving in various leadership roles within the university [4]. - The appointment of Fan Daidi complies with the management regulations for leadership personnel in public institutions in Shaanxi Province, confirming her eligibility for the role [4].

截至2025年5月20日 09:35，恒生医疗保健指数(HSHCI)强势上涨2.69%，成分股三生制药(01530)上涨33.93%，欧康维视生物-B(01477)上涨7.44%，再鼎医药 (09688)上涨6.39%，石药集团(01093)，诺诚健华(09969)等个股跟涨。恒生医疗ETF(513060)高开高走上涨2.48%，冲击3连涨。最新价报0.50元。流动性方 面，恒生医疗ETF盘中换手2.6%，成交2.66亿元。拉长时间看，截至5月19日，恒生医疗ETF近1月日均成交12.37亿元，居可比基金第一。 湘财证券指出，近期在国家鼓励创新大背景下创新药产业链表现活跃，虽然医药工业复苏仍有待验证，行业受医保控费压力仍在，但多层次的支付体系正在 建立，医疗需求的刚性将共同推动行业企稳回升，建议关注高成长及预期改善两大方向，具体而言：（1）高成长：医药外包服务中的ADCCDMO、减肥药 产业链多肽CDMO等方向公司。（2）预期改善：盈利能力有望触底回升的第三方检验医学实验室，消费医疗中的眼科及口腔等方向的公司。 恒生医疗ETF紧密跟踪恒生医疗保健指数，恒生医疗保健指数提供一项市场参考指标，反映在香港上市、主要 ...

对玻尿酸（透明质酸）、重组胶原蛋白两种流行医美原料的比较，引发了医美巨头华熙生物(688363)对 多家券商研报的公开"声讨"。 深夜发文"声讨" 5月17日晚23时许，华熙生物官方微信号发文《概念总在重演，科技永远向前》，将矛头指向多家券商 研报，相关研报提出胶原蛋白在皮肤修复、抗衰老和副作用等方面强于玻尿酸。 华熙生物在微信文章中表示，2022年开始，随着资本市场不断追求新的公司题材，重组胶原蛋白概念被 看似幸运地选中了。为了营造比透明质酸产业更大的预期，围绕某重组胶原企业的研报中，出现了大量 直接针对中国透明质酸产业的所谓"对比研究"。 包括华泰证券、安信证券等多家券商研报被华熙生物节选发在了上述文章中。华熙生物文章称，这些误 导性"结论"伴随着随后兴起的"玻尿酸过时论"被媒体和自媒体红人广泛传播，形成了资本市场与消费市 场的舆论共振，伤害了经几代人努力的、一个中国优势产业的市场转化基础。 华熙生物表示，透明质酸这一成分及相关产业在近几年资本市场的概念切换中遭遇了谎言与践踏，被描 述为"过时""不如某物质安全""不如某物质更具生物活性""不如某物质具备市场价值"……这些抹黑与受 操控的自媒体及网络上的虚 ...

Core Viewpoint - The medical beauty industry is experiencing a significant performance divergence among listed companies, driven by a shift from hyaluronic acid to collagen products, indicating a potential restructuring of industry value logic [1][3]. Group 1: Performance Analysis - In 2024, the performance of upstream medical beauty companies showed significant divergence, with companies like Juzi Biological and Jinbo Biological leading with high growth rates, while major hyaluronic acid players like Aimeike, Huaxi Biological, and Haohai Biological faced pressure [2][3]. - Aimeike's revenue growth slowed to 5.45%, the lowest since its listing, while Huaxi Biological's revenue declined by 11.61% and net profit dropped by 70.59% [3][5]. - Juzi Biological achieved revenue of 5.539 billion, a year-on-year increase of 57.2%, and a net profit of 2.062 billion, up 42.4% [5][7]. Group 2: Market Trends - The market for recombinant collagen products in China is projected to grow from 18.5 billion in 2022 to 108.3 billion by 2027, with a compound annual growth rate of 42.4% [7]. - Companies are increasingly entering the collagen market, including Aimeike and Huaxi Biological, which are exploring new opportunities in this segment [7][8]. - Huaxi Biological is developing proprietary recombinant human collagen products that have entered clinical trials, indicating a strategic shift towards innovative product development [7].

Core Insights - The analysis focuses on the financial performance of 17 representative listed companies in the daily chemical skincare industry, highlighting the significant disparity between sales gross margin and net profit margin [1][2]. Group 1: Financial Performance - In 2024, nearly 80% of the selected companies reported a sales gross margin exceeding 50%, with some companies achieving gross margins over 75% [1][2]. - The industry shows a trend of high gross margins but low net profit margins, with 70% of companies having net profit margins below 15% [1][2]. - The top three companies in terms of sales gross margin are Jinbo Biological (92.02%), Juzhi Biological (82.09%), and Fulejia (81.73%) [2]. Group 2: Sales Net Margin Analysis - The leading companies in sales net margin are Jinbo Biological (50.68%), Juzhi Biological (37.22%), and Fulejia (32.78%) [4]. - Companies such as Jiaheng Household Chemicals (-2.57%), Shanghai Household Chemicals (-14.67%), and Yixian E-commerce (-20.9%) exhibit significantly low net profit margins [4]. Group 3: Industry Challenges - The high sales expenses in the daily chemical skincare industry are identified as a primary reason for the low net profit margins, as substantial marketing costs erode profits [2]. - Qing Song Co. has the lowest sales gross margin at 17.42%, attributed to its positioning as an OEM, facing intense competition from thousands of domestic cosmetic OEMs [6]. - Yixian E-commerce's negative net profit margin of -20.9% is linked to ongoing losses and high marketing expenditures [6].

Group 1 - The Hang Seng Medical Index ETF has shown significant liquidity with a turnover of 1% and a transaction volume of 2.6148 million yuan, with an average daily transaction volume of 27.4616 million yuan over the past month [2] - The ETF's scale has increased by 28.6087 million yuan in the past month, ranking first among comparable funds, with a share increase of 12 million units in the last two weeks, also the highest among peers [2] - In terms of capital inflow, the ETF has seen net inflows on 5 out of the last 8 trading days, totaling 14.5271 million yuan [2] - The current price-to-earnings ratio (PE-TTM) of the Hang Seng Medical Healthcare Index is 23.4, which is in the 4.36% percentile over the past year, indicating a valuation lower than 95.64% of the time in the past year, suggesting historical low valuations [2] - The top ten weighted stocks in the Hang Seng Medical Healthcare Index account for 57.09% of the index, including companies like WuXi Biologics and BeiGene [2] Group 2 - Since the reform of new drug research and development policies in 2015, China's innovative drug industry has developed a strong ecosystem, integrating excellent resources in preclinical and clinical stages, which has gained recognition from multinational corporations (MNCs) [3] - The pharmaceutical and biotechnology sector's Q1 2025 financial reports show stable revenue and profit performance, with notable improvements in certain sub-industries, indicating a return of market enthusiasm for the sector [3] - There is a recommendation to focus on international biotech companies, revaluation of innovative pipelines in generic companies, and companies in the CXO industry with significant order and operational improvements [3] - Investors without stock accounts can access investment opportunities in the Hong Kong medical sector through the Hang Seng Medical Index ETF linked fund (018433) [3]